Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.68 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | INSR | P06213 | 1/20 | 0.64 |
| ▸ | FBP1 | P09467 | 1/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.64 |
| ▸ | FLT4 | P35916 | 1/20 | 0.64 |
| ▸ | CLK1 | P49759 | 1/20 | 0.64 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.64 |
| ▸ | TEK | Q02763 | 1/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27315319 | 0.88 | EGFR (0.81) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL27315311 | 0.87 | EGFR (0.80) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL27315318 | 0.85 | ERBB2 (0.79) | EGFRKDRERBB2EPHB4 | |
| SCHEMBL10037581 | 0.83 | EGFR (0.77) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL208863 | 0.83 | EGFR (0.77) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL29623592 | 0.83 | EGFR (0.77) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL117984 | 0.83 | EGFR (0.77) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL5412843 | 0.82 | EGFR (0.84) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL28907231 | 0.82 | EGFR (0.84) | EGFRKDRAURKAERBB2INSR | |
| SCHEMBL11113 | 0.81 | EGFR (1.00) | EGFRKDRAURKAERBB2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059668-A2 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-03-21 | — | — | WO | disclosed |